ATE215831T1 - Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide - Google Patents

Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide

Info

Publication number
ATE215831T1
ATE215831T1 AT95907978T AT95907978T ATE215831T1 AT E215831 T1 ATE215831 T1 AT E215831T1 AT 95907978 T AT95907978 T AT 95907978T AT 95907978 T AT95907978 T AT 95907978T AT E215831 T1 ATE215831 T1 AT E215831T1
Authority
AT
Austria
Prior art keywords
mage
monoclonal antibodies
tumor
bind
repellant
Prior art date
Application number
AT95907978T
Other languages
English (en)
Inventor
Yao-Tseng Chen
Elisabeth Stockert
Yachi Chen
Pilar Garin-Chesa
Wolfgang J Rettig
Der Bruggen Pierre Van
Thierry Boon-Falleur
Lloyd J Old
Original Assignee
Ludwig Inst Cancer Res
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Sloan Kettering Inst Cancer filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE215831T1 publication Critical patent/ATE215831T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95907978T 1994-02-01 1995-01-05 Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide ATE215831T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/190,411 US5541104A (en) 1991-05-23 1994-02-01 Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
PCT/US1995/000095 WO1995020974A1 (en) 1994-02-01 1995-01-05 Monoclonal anbibodies which bind to tumor rejection antigen precursor mage-1, recombinant mage-1, and mage-1 derived immunogenic peptides

Publications (1)

Publication Number Publication Date
ATE215831T1 true ATE215831T1 (de) 2002-04-15

Family

ID=22701236

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907978T ATE215831T1 (de) 1994-02-01 1995-01-05 Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide

Country Status (16)

Country Link
US (2) US5541104A (de)
EP (1) EP0752876B1 (de)
JP (1) JPH09511389A (de)
CN (1) CN1145032A (de)
AT (1) ATE215831T1 (de)
AU (1) AU686314B2 (de)
CA (1) CA2182369A1 (de)
DE (1) DE69526339T2 (de)
DK (1) DK0752876T3 (de)
ES (1) ES2174931T3 (de)
FI (1) FI963033A0 (de)
NO (1) NO963120L (de)
NZ (1) NZ279377A (de)
PT (1) PT752876E (de)
WO (1) WO1995020974A1 (de)
ZA (1) ZA95786B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40089E1 (en) * 1991-05-23 2008-02-19 Ludwig Institute For Cancer Research Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor
US5925729A (en) * 1991-05-23 1999-07-20 Ludwig Institute For Cancer Research Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US6060257A (en) * 1994-06-03 2000-05-09 Ludwig Institute For Cancer Research Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof
KR0185334B1 (ko) * 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2309765A1 (en) * 1997-12-18 1999-06-24 G.D. Searle & Co. Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity
BR9907691B1 (pt) 1998-02-05 2011-05-31 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7851212B2 (en) 2000-05-10 2010-12-14 Sanofi Pasteur Limited Immunogenic polypeptides encoded by MAGE minigenes and uses thereof
US7393657B2 (en) 2001-04-12 2008-07-01 Imperial College Innovations Limited Diagnosis and treatment of cancer: I
ATE369895T1 (de) 2002-04-09 2007-09-15 Sanofi Pasteur Ltd Modifizierte cea nucleinsäure und expressionsvektoren
WO2005035773A2 (en) * 2003-10-08 2005-04-21 Sanofi Pasteur, Inc. Modified cea /b7 vector
FR2889959A1 (fr) * 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US9175070B2 (en) 2009-09-25 2015-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
ES2916217T3 (es) 2017-01-05 2022-06-29 Kahr Medical Ltd Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
DK3565579T3 (da) 2017-01-05 2023-09-04 Kahr Medical Ltd Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
US20210187023A1 (en) 2017-06-27 2021-06-24 The Trustees Of Princeton University Compositions And Methods For Enhancing Immunotherapy
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
CN111836635A (zh) 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
CA3104780A1 (en) 2018-07-11 2020-01-16 Kahr Medical Ltd. Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
US12329816B2 (en) 2018-08-24 2025-06-17 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
BR112022000319A2 (pt) 2019-07-11 2022-03-15 Kahr Medical Ltd Heterodímeros e métodos de uso dos mesmos
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
US20230048719A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
US20240317871A1 (en) 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
EP4430402A1 (de) 2021-11-09 2024-09-18 T-Knife GmbH Verfahren zur selektierung von mage-a1 positiven tumoren
GB202303250D0 (en) 2023-03-06 2023-04-19 King S College London Method and compounds
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
GB202501534D0 (en) 2025-02-03 2025-03-19 Cambridge Entpr Ltd Targeted phagocytic degradation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
KR950003005B1 (ko) * 1992-04-09 1995-03-29 주식회사 진흥전자 자동소변세척기
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern

Also Published As

Publication number Publication date
CN1145032A (zh) 1997-03-12
PT752876E (pt) 2002-09-30
FI963033L (fi) 1996-07-31
US5843448A (en) 1998-12-01
ZA95786B (en) 1995-10-09
US5541104A (en) 1996-07-30
FI963033A7 (fi) 1996-07-31
DE69526339D1 (de) 2002-05-16
NO963120L (no) 1996-09-30
AU1597995A (en) 1995-08-21
FI963033A0 (fi) 1996-07-31
ES2174931T3 (es) 2002-11-16
NO963120D0 (no) 1996-07-26
DK0752876T3 (da) 2002-05-21
EP0752876B1 (de) 2002-04-10
AU686314B2 (en) 1998-02-05
NZ279377A (en) 1997-07-27
EP0752876A1 (de) 1997-01-15
DE69526339T2 (de) 2003-01-02
EP0752876A4 (de) 1999-07-07
CA2182369A1 (en) 1995-08-10
JPH09511389A (ja) 1997-11-18
WO1995020974A1 (en) 1995-08-10

Similar Documents

Publication Publication Date Title
DE69526339D1 (de) Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide
DE69429095D1 (de) Humanisierte antikoerper
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
RU94045919A (ru) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
DE69433663D1 (de) Antikörper gegen menschliches prostatspezifisches drüsenkallikrein
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
DE69733960D1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
EA200601715A1 (ru) Получение гуманизированных антител в [организме] трансгенных животных
CA2149120A1 (en) Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof
ATE497004T1 (de) Moraxella catarrhalis antigene uspa1 und uspa2
RU2008100239A (ru) Терапевтические связывающие молекулы в виде химерного антитела
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DE3854904D1 (de) Peptide, die von der Faktor VIII-Bindungsdomäne des von Willebrand-Faktors abgeleitet sind
ATE332914T1 (de) Mimotope und antimimotope des menschlichen plättchen-glykoproteins ib/ix
EP0784684B8 (de) Rekombinantpeptide hergeleitet vom mc3 antikörper gegen ba46, verfahren zu deren verwendung und verfahren zur humanisierung von antikörperpeptiden
HUP0103573A2 (hu) Trombózis elleni hatóanyag és von Willebrand faktor elleni monoklonális antitest
DE60114829D1 (de) Variable region des monoklonalen antikörpers gegen das hbv s-oberflächenantigen und für diese kodierendes gen
ATE285418T1 (de) Humanisierter antikörper spezifisch für das oberflächenantigen pre-s1 von hbv und dessen präparation
ES2143996T3 (es) Antigenos peptidicos del hcv y procedimiento para la determinacion del hcv.
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
DK0472706T3 (da) Induktion af beskyttelse mod viral infektion
RU94046321A (ru) Моноклональные муриновые антиидиотипические антитела, способ их получения и их применение, способы иммунизации и фармацевтический состав на их основе
DE69617255D1 (de) Durch hla-b44 moleküle präsentierte tumor-abstossungsantigene und ihre verwendung
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
ES2088820A1 (es) Anticuerpos monoclonales antineumolisina.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0752876

Country of ref document: EP